info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
United States Flag  US: +1-315-636-4233    United Kingdom Flag  UK: +44-162-237-0614    Indian Flag  IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Press Releases » Global Congestive Heart-Failure (CHF) Treatment Devices Market is poised to grow to USD 35.97 Bn by 2030 with a steady CAGR of 8.31%.

Global Congestive Heart-Failure (CHF) Treatment Devices Market is poised to grow to USD 35.97 Bn by 2030 with a steady CAGR of 8.31%.


Published Date: Apr-2022 | Report Format:Electronic (PDF)

The report ' Global Congestive Heart Failure (CHF) Treatment Devices ' Market by Type (Cardiac Resynchronization Therapy (CRT), Implantable Cardioverter Defibrillators (ICDs)), By End-user (Hospitals and clinics, Specialized Cardiovascular Disease Treatment Centers, Ambulatory surgery centres) and By Region (North America, Latin America, Europe, Asia Pacific and the Middle East & Africa). With a market size of USD 16.19 bn in 2020, the Global Congestive Heart Failure (CHF) Treatment Devices Market Size will grow to USD 35.97 bn by 2030 with a CAGR of 8.31 %.

 

To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/congestive-heart-failure-treatment-devices-market

 

Key Factors that are expediting the Market growth

Poor nutrition, a lack of exercise, changing lifestyles, rising stress, unhealthy weight gain, and increased smoking and alcohol consumption are all factors. Furthermore, illnesses such as coronary artery disease, sleep apnea, heart defects, irregular heartbeats, diabetes mellitus, obesity, and kidney problems all contribute to the occurrence of chronic heart failure and have a synergistic effect.

 

By Product, Implantable Cardioverter Defibrillators (ICDs) have the largest market share.

ICDs are the industry leader because of their numerous applications. The majority of contemporary ICDs may function as a pacemaker as well as a defibrillator. When there is an aberrant heartbeat, many ICDs also record the electrical patterns of the heart. This can assist the doctor in developing a treatment strategy for the future.

 

By End-User, the Hospital segment is projected to show sheer dominance.

The hospital segment leads the market due to better availability of surgeons, safe practices, and higher efficiencies.

 

THE REGION NORTH AMERICA IS PREDICTED TO BE THE LARGEST MARKET, FOLLOWED BY EUROPE

North America & Europe are comprehensively leading the market due to the high number of cardiovascular disorders and ageing population. 

The Asia-Pacific region was regarded as the fastest Growing Market due to the higher aged population of India and China.

 

IMPORTANT MARKET PLAYERS:

Some of the leading key players in the Global Congestive Heart Failure (CHF) Treatment Devices Market include -Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.

 

Recent Developments

  • In February 2022, Medtronic received FDA expanded approval for cardiac cryoablation catheters for the pediatric treatment of a common heart rhythm condition.
  • In August 2021, BoehringerIngelheim and Eli Lilly & Company got the US FDA approval to reduce the risk of cardiovascular mortalities and hospitalization in individuals with heart failure with reduced ejection fraction (HFrEF). However, Jardiance is not for people with type 1 diabetes.
  • In June 2021, Abbott Confirmed the Capacity to Support the Expanded Use of Heartmate 3 Heart Pump, mechanical devices for heart failure.
  • In Feb 2021, the FDA approved Entresto, a combination of sacubitril and valsartan, for the treatment of heart failure (HF) patients with preserved ejection fraction (HFpEF).
  • In May 2020, U.S. FDA approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.
  • In August 2019, CVRx Received FDA Approval for World's First Heart Failure Neuromodulation Device
  • In June 2021, the American College of Cardiology (ACC) and GE Healthcare collaborated to support and participate in ACC's Applied Health Innovation Consortium to build a roadmap for artificial intelligence (AI) and digital technology in cardiology and to develop new strategies for improved health outcomes.
  • In February 2021, Teleflex Acquired of Z-Medica, an industry-leading manufacturer of haemostatic products.

Choose License Type



$0
$0
$0
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: (+1) 315-636-4233
  • UK: (+44) 1622-370-614
  • IN: (+91) 826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved